Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 2
1995 1
1996 2
1997 1
1999 3
2000 5
2001 6
2002 3
2003 7
2004 2
2005 5
2006 6
2007 2
2008 11
2009 8
2010 13
2011 6
2012 4
2013 8
2014 8
2015 2
2016 2
2018 1
2020 2
2021 4
2022 2
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV.
Rolle CP, Berhe M, Singh T, Ortiz R, Wurapa A, Ramgopal M, Leone PA, Matthews JE, Dalessandro M, Underwood MR, Angelis K, Wynne BR, Merrill D, Nguyen C, van Wyk J, Zolopa AR. Rolle CP, et al. Among authors: zolopa ar. AIDS. 2021 Oct 1;35(12):1957-1965. doi: 10.1097/QAD.0000000000002979. AIDS. 2021. PMID: 34115650 Free PMC article. Clinical Trial.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Orkin C, Schapiro JM, Perno CF, Kuritzkes DR, Patel P, DeMoor R, Dorey D, Wang Y, Han K, Van Eygen V, Crauwels H, Ford SL, Latham CL, St Clair M, Polli JW, Vanveggel S, Vandermeulen K, D'Amico R, Garges HP, Zolopa A, Spreen WR, van Wyk J, Cutrell AG. Orkin C, et al. Among authors: zolopa a. Clin Infect Dis. 2023 Nov 17;77(10):1423-1431. doi: 10.1093/cid/ciad370. Clin Infect Dis. 2023. PMID: 37340869 Free PMC article.
Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.
Rolle CP, Berhe M, Singh T, Ortiz R, Wurapa A, Ramgopal M, Jayaweera DT, Leone PA, Matthews JE, Cupo M, Underwood MR, Angelis K, Wynne BR, Merrill D, Nguyen C, van Wyk J, Zolopa AR. Rolle CP, et al. Among authors: zolopa ar. Open Forum Infect Dis. 2023 Mar 1;10(3):ofad101. doi: 10.1093/ofid/ofad101. eCollection 2023 Mar. Open Forum Infect Dis. 2023. PMID: 36968959 Free PMC article.
Gender inequality and HIV transmission: a global analysis.
Richardson ET, Collins SE, Kung T, Jones JH, Hoan Tram K, Boggiano VL, Bekker LG, Zolopa AR. Richardson ET, et al. Among authors: zolopa ar. J Int AIDS Soc. 2014 Jun 27;17(1):19035. doi: 10.7448/IAS.17.1.19035. eCollection 2014. J Int AIDS Soc. 2014. PMID: 24976436 Free PMC article.
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
Fernvik E, Sierra Madero J, Espinosa N, Gulminetti R, Hagins D, Tsai HC, Man C, Sievers J, Grove R, Zolopa A, Wynne B, van Wyk J, Ait-Khaled M. Fernvik E, et al. Among authors: zolopa a. J Acquir Immune Defic Syndr. 2023 Nov 1;94(3):e9-e12. doi: 10.1097/QAI.0000000000003280. J Acquir Immune Defic Syndr. 2023. PMID: 37850985 No abstract available.
118 results